<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225261</url>
  </required_header>
  <id_info>
    <org_study_id>173003</org_study_id>
    <nct_id>NCT03225261</nct_id>
  </id_info>
  <brief_title>The Effect of Citrus Extract on Gastrointestinal Health</brief_title>
  <official_title>The Effect of Citrus Extract Administration on Gastrointestinal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, parallel, double-blind, placebo-controlled trial aims to determine the
      effects of daily administration of citrus extract over a period of 8 weeks on
      gastrointestinal health in 2 different patient groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect on intestinal inflammation, measured by fecal calprotectin levels.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary objective is to assess the effect of 500 mg citrus extract on intestinal inflammation after 8 weeks of administration, by measuring fecal calprotectin in UC patients in remission and in IBS patients with moderately increased fecal calprotectin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect on microbial metabolic activity, measured by fecal short chain fatty acids (SCFA).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on fecal microbiota composition, assessed by next generation sequencing.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on fecal microbiota functional capacity, assessed by next generation sequencing.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on the systemic immune response, measured by cytokine production capacity of stimulated whole blood</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on disease symptoms, measured by patient reported outcomes (GSRS).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on disease symptoms, measured by patient reported outcomes (symptom diary).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on stool frequency, measured by Bristol Stool Chart.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on stool consistency, measured by Bristol Stool Chart.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on blood markers for oxidative stress, measured by MDA concentration in blood.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on blood markers for antioxidant capacity, measured by blood total antioxidant capacity.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Citrus extract UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrus extract, patients with ulcerative colitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo UC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin, patients with ulcerative colitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citrus extract IBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrus extract, patients with irritable bowel syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IBS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin, patients with irritable bowel syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus extract</intervention_name>
    <description>Citrus extract</description>
    <arm_group_label>Citrus extract UC</arm_group_label>
    <arm_group_label>Citrus extract IBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo UC</arm_group_label>
    <arm_group_label>Placebo IBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria IBD:

          -  Patients with quiescent ulcerative colitis

          -  Calprotectin levels 50-150µg/g feces.

          -  Stable use of 5-ASA for at least 3 months prior and during the study.

          -  Age 18-70 years

          -  BMI &lt; 35 kg/m2

        Inclusion Criteria IBS:

          -  Patients with IBS

          -  Calprotectin levels 15-150 µg/g feces

          -  Age 18-70 years

          -  BMI &lt; 35 kg/m2

        Exclusion Criteria:

          -  Comorbidities that may influence gut microbiota composition or which might limit
             participation in or completion of the study protocol (to be decided by the principle
             investigator)

          -  Abdominal surgery interfering with gastrointestinal function (to be decided by the
             principle investigator)

          -  Use of immunosuppressive drugs within 3 months before study period

          -  Use of other medication interfering with endpoints

          -  Changes in medication that may significantly affect the study outcome according to the
             investigator's judgment within 1 month prior to the study

          -  Changes in clinical activity scores within 3 weeks prior to the study

          -  Administration of investigational drugs or participation in any scientific
             intervention study which may interfere with this study (to be decided by the principle
             investigator) in the 180 days prior to the study

          -  Use of dietary supplements containing antioxidants, minerals and vitamins

          -  Excessive intake of foods with a high polyphenol concentration

          -  Use of antibiotics within 3 months prior to the start of study

          -  Use of pre-or probiotics within 1 month prior to the study

          -  Use of oral corticosteroids within 1 month prior to the study

          -  Blood donation within 1 month prior to the study

          -  Known pregnancy or lactation.

          -  Smoking

          -  Excessive drinking (&gt;20 alcoholic consumptions per week)

          -  History of any side effects towards the intake of flavonoids or citrus fruits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad Masclee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yala Stevens, MSc</last_name>
    <phone>+31 43 3884295</phone>
    <email>yala.stevens@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yala Stevens, MSc</last_name>
      <phone>+31 43 3884295</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Yala Stevens</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

